問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2449Cases

2021-11-01 - 2030-12-01

Phase III

Active
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    膠囊劑 皮下注射劑 錠劑 凍晶注射劑及懸浮注射液

Participate Sites
7Sites

Recruiting7Sites

2022-06-01 - 2027-10-31

Phase II

Active
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Condition/Disease

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Test Drug

    Efgartigimod (ARGX-113)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated5Sites

2024-02-12 - 2026-06-01

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjogren's Syndrome With Moderate-to-Severe Symptom State

  • Condition/Disease

    Sjogren's Syndrome

  • Test Drug

    Dazodalibep

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2027-12-31

Phase II

Active
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

  • Condition/Disease

    SYSTEMIC LUPUS ERYTHEMATOSUS

  • Test Drug

    injection

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2025-09-24 - 2028-11-30

Phase I

Not yet recruiting
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants with Advanced Solid Tumors, Including Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Solid Tumors, Including Hepatocellular Carcinoma

  • Test Drug

    ZW251

Participate Sites
3Sites

Recruiting3Sites

2024-07-01 - 2027-01-31

Phase II

Active
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    injection

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2023-06-28 - 2027-03-31

Phase III

Active
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • Test Drug

    GIREDESTRANTEVEROLIMUSEXEMESTANETAMOXIFENFULVESTRANT

Participate Sites
6Sites

Recruiting6Sites

2025-02-01 - 2025-08-05

Phase II

Completed
A multinational, multicenter, double-blind, placebo-controlled Phase 2 study to evaluate efficacy and safety of SAR444656 in adult participants with moderate to severe atopic dermatitis

  • Condition/Disease

    moderate to severe atopic dermatitis

  • Test Drug

    tablet

Participate Sites
4Sites

Recruiting4Sites

2022-12-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-13 - 2030-06-30

Phase III

Active
An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN) [PROMINENT]

  • Condition/Disease

    Primary Membranous Nephropathy (PMN)

  • Test Drug

    powder

Participate Sites
10Sites

Recruiting10Sites

1 50 51 52 53 54 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB